
Join to View Full Profile
3036 NE Martin Luther King Jr BlvdPortland, OR 97212
Dr. Turner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Erick Turner is a psychiatrist based in Portland, OR. He graduated from Oregon Health & Science University, did psychiatry residency at the University of California, Irvine, then a research fellowship at the National Institute of Mental Health (NIMH). He then worked as a Medical Officer (Clinical Reviewer) at the FDA, reviewing new drug applications submitted by drug companies in order to determine whether these drugs should be approved for the US market. That experience made him aware of the vast amounts of clinical drug trial data that never see the light of day in journal publications. This inspired his later research on publication bias. His best-known paper, entitled "Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy", was published in the NEJM in 2008. It received widespread coverage in the international press. According to Scopus, it has been cited over 1,900 times, including over 130 books and book chapters, placing it in the 99th percentile. Currently, Dr. Turner is Professor Emeritus in the Department of Psychiatry at Oregon Health and Science University.
Education & Training
- National Institutes of Health Clinical CenterResidency, Psychiatry, 1992 - 1998
- University of California (Irvine)Residency, Psychiatry, 1989 - 1992
- Oregon Health and Science University School of MedicineClass of 1989
Certifications & Licensure
- MD State Medical License 1993 - 2025
- OR State Medical License 2023 - 2025
- CA State Medical License 1990 - 1992
- American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- Characteristics of Trials Preceding FDA Approval of Novel Psychiatric Drugs.Rosa Y Ahn-Horst, Erick H Turner, Aaron S Kesselheim
JAMA Network Open. 2025-01-02 - 2 citationsFragile promise of psychedelics in psychiatry.Cédric Lemarchand, Raphaël Chopin, Morgane Paul, Alain Braillon, Lisa Cosgrove
BMJ. 2024-11-19 - Unpublished trials of alprazolam XR and their influence on its apparent efficacy for panic disorder.Rosa Y Ahn-Horst, Erick H Turner
Psychological Medicine. 2024-04-01
Press Mentions
- An Old-but-New Treatment for Opioid AddictionApril 2nd, 2021
- What to Do When Pandemic Stress Meets Seasonal Depression Caused by Lack of LightOctober 13th, 2020
- Experts Weigh in on Esketamine's Approval for People with Suicidal ThoughtsAugust 10th, 2020
- Join now to see all
Professional Memberships
- American Society of Clinical PsychopharmacologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: